Therapeutic options for HCV - Management of the infected individual

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 14, Issue 2, 2000, Pages 255-264

  Foster, G R ^b   Thomas, H C ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Guidelines; Hepatitis C; Interferon; Ribavirin

Indexed keywords

ALPHA INTERFERON; AMANTADINE; ANTIVIRUS AGENT; MACROGOL; RIBAVIRIN;

DISEASE SEVERITY; FOLLOW UP; GENOTYPE; HEPATITIS C; HISTOLOGY; HUMAN; LIVER BIOPSY; LIVER HISTOLOGY; PRACTICE GUIDELINE; REVIEW; VIRUS REPLICATION;

EID: 0034049736     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.1999.0074     Document Type: Article

References (30)

1. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 349:1997;825-832.
2. Foster G R, Goldin R D, Main J. The management of chronic hepatitis C: clinical audit of a biopsy based management algorithm. British Medical Journal. 315:1997;453-458.
3. Panel N C. National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology. 26:1997;2S-11S.
4. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology. 26:1997;133S-136S.
5. Tibbs C. Methods of transmission of hepatitis C. Journal of Viral Hepatitis. 2:1995;113-120.
6. Foster G R, Goldin R D, Thomas H C. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 27:1998;209-212.
7. Ishak K, Bapista A, Bianchi L. Histological grading and staging of chronic hepatitis. Journal of Hepatology. 22:1995;696-699.
8. Hoofnagle J H, Mullen K D, Jones D B. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. New England Journal of Medicine. 315:1986;1575-1578.
9. Cimino L, Nardone G, Citarella C. Treatment of chronic hepatitis C with recombinant interferon alfa. Italian Journal of Gastroenterology. 23:1991;399-402.
10. McHutchison J G, Gordon S C, Schiff E R. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine. 339:1998;1485-1492.
11. Saracco G, Rosina F, Abate M. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b. Hepatology. 18:1993;1300-1305.
12. Marcellin P, Boyer N, Gervais A. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Annals of Internal Medicine. 127:1997;875-881.
13. Chemello L, Bonetti P, Cavalletto L. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology. 22:1995;700-706.
14. Poynard T, Bedossa P, Chevallier M. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. New England Journal of Medicine. 332:1995;1457-1462.
15. Poynard T, Leroy V, Cohard M. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 24:1996;778-789.
16. Shiffman M L. Use of high-dose interferon in the treatment of chronic hepatitis C. Seminars in Liver Disease. 19:1999;25-33.
17. Smith R. Background and mechanisms of action of ribavirin. Smith R A, Knight V, Smith J. Clinical Applications of Ribavirin. 1984;1-18 Academic Press, London.
18. Bodenheimer H C Jr, Lindsay K L, Davis G L. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 26:1997;473-477.
19. Davis G L, Esteban-Mur R, Rustigi V. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. New England Journal of Medicine. 339:1998;1493-1499.
20. Poynard T, Marcellin P, Lee S S. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 352:1998;1426-1432.
21. Davis G L. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Seminars in Liver Disease. 19:1999;49-55.
22. Zeuzem S, Schmidt J M, Lee S H. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology. 28:1998;245-252.
23. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. Journal of Hepatology. 24:1996;38-47.
24. Heathcote J. Consensus interferon: a novel interferon for the treatment of hepatitis C. Journal of Viral Hepatitis. 5:1998;13-18.
25. Cooksley W G. Interferon treatment of chronic hepatitis C with cirrhosis. Journal of Viral Hepatitis. 4:1997;85-88.
26. Fattovich G, Giustina G, Degos F. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 112:1997;463-472.
27. Bottelli R, Tibballs J, Hochhauser D. Ultrasound screening for hepatocellular carcinoma (HCC) in cirrhosis: the evidence for an established clinical practice. Clinical Radiology. 53:1998;713-716.
28. Dioguardi N. Early diagnosis of hepatocellular carcinoma in Italy: a summary of a consensus conference held in Milan by the Italian Association for the Study of the Liver. Journal of Hepatology. 14:1992;410-413.
29. Younossi Z M, Perrillo R P. The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Seminars in Liver Disease. 19:1999;95-102.
30. Foster G R. Amantadine in the treatment of patients with chronic hepatitis C. Italian Journal of Gastroenterology and Hepatology. 30:1998;614-615.